Clinical Trials Browser

Phase 2 × INDUSTRY × Neoplasms, Squamous Cell × Clear all

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT00272181 2015-12-23

Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer

Phase 2 Terminated

15 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasms, Squamous Cell

NCT00229723 2009-08-04

IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2 Completed

224 enrolled 21 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Neoplasms, Squamous Cell

NCT00255476 2009-04-23

The IRESSA Novel Head and Neck Chemotherapy Evaluation Study

Phase 2 Completed

64 enrolled

Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

Clinical Trials

Zalutumumab in Non-curable Patients With SCCHN

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer

IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma

The IRESSA Novel Head and Neck Chemotherapy Evaluation Study